Bold Moves

Transform our go-to-market model

Lead the conversation

Pfizer has teamed up with one of China’s largest insurers to help more Chinese patients access the medicines they need

China’s public health system, like many others in the world, is under increasing pressure from an expanding middle class, aging population, a shifting burden of disease and the current global pandemic. As a result, it’s becoming more challenging for the government to provide affordable access to new, innovative medicines under its national basic medical insurance program.

Pfizer has partnered with one of China’s largest insurers, Ping An, to find new ways to help relieve this pressure. In November, Pfizer and Ping An signed a memorandum of understanding to explore innovative commercial health insurance models.

International experience shows us that commercial health insurance can help expand access to health care, including access to innovative medicines. Commercial health insurance can also help to reduce out-of-pocket costs for patients, improve quality of care and support the promotion of healthy lifestyles and disease prevention."

Dr. Albert Bourla

Chairman and Chief Executive Officer, Pfizer

Pfizer and Ping An will seek to collaborate with a city or provincial government to pilot a new insurance model underpinned by a cutting-edge clinical decision support system and smart-tech prevention and patient support platforms. The partners will also seek to engage in strategic, high-level advocacy to help shape the policy environment for China’s nascent commercial health insurance industry.


Only 20% of new medicines launched globally in the past decade are available in China. Among these, fewer than 40% are included in the National Reimbursement Drug List.1

The overall goal of this project is to demonstrate that commercial health insurance is a sustainable option to increase access to innovative medicines in China, with the pharmaceutical industry as a critical partner.

Albert Bourla discussing how commercial health insurance can improve health system resiliency at the China Development Forum in November.


1PhRMA maintains a global database of the availability of new medicines in countries around the world. The availability is based on sales in a given country as reported by IQVIA.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on Pfizer.com.

Visit Pfizer.com


Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories